Kandice Kottke-Marchant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kandice Kottke-Marchant has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Roger E. Marchant
Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio
4 shared publicationsAlexander Duncan
2 shared publicationsDeepak L. Bhatt
Brigham and Women's Hospital Heart & Vascular Center, and Harvard Medical School, Boston, MA, USA
2 shared publicationsGeorge Corcoran
2 shared publications- Megan O. Nakashima
Robert J. Tomsich Department of Pathology and Laboratory Medicine, Diagnostic Institute, Cleveland Clinic, Cleveland, USA
2 shared publications Philip Comp
2 shared publications
Latest Publications
- 5 January 2021
- Published by Springer Nature
- p. 25-32
Platelets
- 26 April 2017
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 39 (S1) , 69-75
Diagnostic approach to microangiopathic hemolytic disorders
Thrombotic micro‐angiopathies (TMA) are a group of related disorders that are characterized by thrombosis of the microvasculature and associated organ dysfunction, and encompass congenital, acquired, and infectious etiologies. A hall mark of TMAs is the fragmentation of erythrocytes by the microvascular thrombi, resulting in a hemolytic anemia. There are several distinct pathophysiologies leading to microangiopathic hemolysis, ranging from decreased degradation of von Willebrand factor as seen in thrombotic thrombocytopenic purpura (TTP) to endothelial damage facilitated by Escherichia coli shiga toxin or complement dysregulation, seen in shiga toxin‐related hemolytic‐uremic syndrome (Stx‐HUS) and complement‐mediated TMA (also called atypical hemolytic‐uremic syndrome), respectively. Distinguishing these disorders is important, as many TMAs are life‐threatening, the treatments are distinct and selecting appropriate therapy can improve patient prognosis. Laboratory testing, including measurement of ADAMTS13, ADAMTS13 inhibitor, shiga toxin, and complement factors, can help establish diagnoses and guide therapy.
- 26 April 2017
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 39 (S1) , 69-75
Diagnostic approach to microangiopathic hemolytic disorders
Thrombotic micro‐angiopathies (TMA) are a group of related disorders that are characterized by thrombosis of the microvasculature and associated organ dysfunction, and encompass congenital, acquired, and infectious etiologies. A hall mark of TMAs is the fragmentation of erythrocytes by the microvascular thrombi, resulting in a hemolytic anemia. There are several distinct pathophysiologies leading to microangiopathic hemolysis, ranging from decreased degradation of von Willebrand factor as seen in thrombotic thrombocytopenic purpura (TTP) to endothelial damage facilitated by Escherichia coli shiga toxin or complement dysregulation, seen in shiga toxin‐related hemolytic‐uremic syndrome (Stx‐HUS) and complement‐mediated TMA (also called atypical hemolytic‐uremic syndrome), respectively. Distinguishing these disorders is important, as many TMAs are life‐threatening, the treatments are distinct and selecting appropriate therapy can improve patient prognosis. Laboratory testing, including measurement of ADAMTS13, ADAMTS13 inhibitor, shiga toxin, and complement factors, can help establish diagnoses and guide therapy.
- 28 July 2016
- Published by Springer Nature
- p. 17-24
Platelets
- 20 July 2016
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 38 (5) , 550-559
Validation of a panel of ADAMTS13 assays for diagnosis of thrombotic thrombocytopenic purpura: activity, functional inhibitor, and autoantibody test
Summary: Introduction: Quantitation of ADAMTS13 activity, functional inhibitors, and autoantibodies is crucial in diagnosis and management of thrombotic thrombocytopenic purpura. We compared and optimized commercial assay kits and validated a testing panel.Methods: Citrated plasma specimens from healthy volunteers and residual samples submitted for clinical testing were used in the study. Commercially available ADAMTS13 activity assays including ACTIFLUOR™ ADAMTS13 (Sekisui Diagnostics, Stamford, CT, USA), LIFECODES ATS‐13 (Gen‐Probe Inc., San Diego, CA, USA), and TECHNOZYM® ADAMTS‐13 (Technoclone, Vienna, Austria) were evaluated. Functional inhibitor assays were performed using internally developed mixing protocols. Two autoantibody assays were also evaluated: IMUBIND® (Sekisui Diagnostics) and TECHNOZYM® ADAMTS‐13 INH ELISA kits (Technoclone).Results: A laboratory‐developed assay using ACTIFLUOR™ reagents showed best agreement with the reference method, and full validation showed a reportable range of 5% (LLOQ) to 114% with a reference interval of ≥68%. Both intra‐ and interassay coefficients of variation were ® autoantibody assay showed 85% overall agreement with the reference method with imprecision approximately 20%.Conclusion: ADAMTS13 activity and inhibitor tests using ACTIFLUOR™ reagents and modified TECHNOZYM® autoantibody ELISA showed superior performance compared to the other kits for clinical use in this study.
- 20 July 2016
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 38 (5) , 550-559
Validation of a panel of ADAMTS13 assays for diagnosis of thrombotic thrombocytopenic purpura: activity, functional inhibitor, and autoantibody test
Summary: Introduction: Quantitation of ADAMTS13 activity, functional inhibitors, and autoantibodies is crucial in diagnosis and management of thrombotic thrombocytopenic purpura. We compared and optimized commercial assay kits and validated a testing panel.Methods: Citrated plasma specimens from healthy volunteers and residual samples submitted for clinical testing were used in the study. Commercially available ADAMTS13 activity assays including ACTIFLUOR™ ADAMTS13 (Sekisui Diagnostics, Stamford, CT, USA), LIFECODES ATS‐13 (Gen‐Probe Inc., San Diego, CA, USA), and TECHNOZYM® ADAMTS‐13 (Technoclone, Vienna, Austria) were evaluated. Functional inhibitor assays were performed using internally developed mixing protocols. Two autoantibody assays were also evaluated: IMUBIND® (Sekisui Diagnostics) and TECHNOZYM® ADAMTS‐13 INH ELISA kits (Technoclone).Results: A laboratory‐developed assay using ACTIFLUOR™ reagents showed best agreement with the reference method, and full validation showed a reportable range of 5% (LLOQ) to 114% with a reference interval of ≥68%. Both intra‐ and interassay coefficients of variation were ® autoantibody assay showed 85% overall agreement with the reference method with imprecision approximately 20%.Conclusion: ADAMTS13 activity and inhibitor tests using ACTIFLUOR™ reagents and modified TECHNOZYM® autoantibody ELISA showed superior performance compared to the other kits for clinical use in this study.
- 16 July 2015
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 104 (1) , 71-81
Dual biofunctional polymer modifications to address endothelialization and smooth muscle cell integration of ePTFE vascular grafts
Expanded polytetrafluoroethylene (ePTFE) grafts were coated on the luminal surface with a cell‐adhesive fluorosurfactant (FSP) polymer to promote endothelialization, followed by ethanol hydration to degas the pores and subsequent cell‐adhesive, enzymatically degradable poly(ethylene glycol)‐based hydrogel incorporation into the graft interstices to accommodate potential smooth muscle cell integration in the graft wall. The FSP coating on ePTFE was stable as demonstrated by a significantly reduced receding water contact angle on FSP‐coated ePTFE (14.5 ± 6.4°) compared to uncoated ePTFE (105.3 ± 4.5°, P < 0.05) after ethanol exposure. X‐ray photoelectron spectroscopy analysis of the same surfaces confirmed FSP presence. Localization of the FSP and hydrogel within the ePTFE graft construct was assessed using fluorescently labeled polymers, and demonstrated hydrogel infiltration throughout the thickness of the graft wall, with FSP coating limited to the lumen and adventitial surfaces. FSP at the luminal surface on dual‐coated grafts was able to bind endothelial cells (EC) (98.7 ± 23.1 cells/mm2) similar to fibronectin controls (129.4 ± 40.7 cells/mm2), and significantly higher than uncoated ePTFE (31.6 ± 19 cells/mm2, P < 0.05). These results indicate that ePTFE grafts can be simultaneously modified with two different polymers that have potential to directly address both endothelialization and intimal hyperplasia. Such a construct is a promising candidate for an off‐the‐shelf synthetic graft for small‐diameter graft applications. © 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 71–81, 2016.
- 16 July 2015
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 104 (1) , 71-81
Dual biofunctional polymer modifications to address endothelialization and smooth muscle cell integration of ePTFE vascular grafts
Expanded polytetrafluoroethylene (ePTFE) grafts were coated on the luminal surface with a cell‐adhesive fluorosurfactant (FSP) polymer to promote endothelialization, followed by ethanol hydration to degas the pores and subsequent cell‐adhesive, enzymatically degradable poly(ethylene glycol)‐based hydrogel incorporation into the graft interstices to accommodate potential smooth muscle cell integration in the graft wall. The FSP coating on ePTFE was stable as demonstrated by a significantly reduced receding water contact angle on FSP‐coated ePTFE (14.5 ± 6.4°) compared to uncoated ePTFE (105.3 ± 4.5°, P < 0.05) after ethanol exposure. X‐ray photoelectron spectroscopy analysis of the same surfaces confirmed FSP presence. Localization of the FSP and hydrogel within the ePTFE graft construct was assessed using fluorescently labeled polymers, and demonstrated hydrogel infiltration throughout the thickness of the graft wall, with FSP coating limited to the lumen and adventitial surfaces. FSP at the luminal surface on dual‐coated grafts was able to bind endothelial cells (EC) (98.7 ± 23.1 cells/mm2) similar to fibronectin controls (129.4 ± 40.7 cells/mm2), and significantly higher than uncoated ePTFE (31.6 ± 19 cells/mm2, P < 0.05). These results indicate that ePTFE grafts can be simultaneously modified with two different polymers that have potential to directly address both endothelialization and intimal hyperplasia. Such a construct is a promising candidate for an off‐the‐shelf synthetic graft for small‐diameter graft applications. © 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 71–81, 2016.
- 1 February 2015
- Published by Elsevier in Acta Biomaterialia
- Vol. 13, 52-60
Photoinitiator-free synthesis of endothelial cell-adhesive and enzymatically degradable hydrogels
- 1 February 2015
- Published by Elsevier in Acta Biomaterialia
- Vol. 13, 52-60
Photoinitiator-free synthesis of endothelial cell-adhesive and enzymatically degradable hydrogels
- 1 December 2014
- Published by Elsevier in Acta Biomaterialia
- Vol. 10 (12) , 5106-5115
Extracellular matrix-mimetic poly(ethylene glycol) hydrogels engineered to regulate smooth muscle cell proliferation in 3-D
- 1 December 2014
- Published by Elsevier in Acta Biomaterialia
- Vol. 10 (12) , 5106-5115
Extracellular matrix-mimetic poly(ethylene glycol) hydrogels engineered to regulate smooth muscle cell proliferation in 3-D
- 1 July 2014
- Published by Elsevier in Thrombosis Research
- Vol. 134 (1) , 96-104
Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy
- 1 July 2014
- Published by Elsevier in Thrombosis Research
- Vol. 134 (1) , 96-104
Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy
- 7 February 2014
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 40 (02) , 195-204
Algorithmic Approaches to Hemostasis Testing
There are many unique issues that may make a pathologist's consultation helpful in hemostasis testing. Besides the rapidly expanding knowledge of both bleeding and thrombotic disorders and a wide test menu, hemostasis testing is very sensitive to preanalytical issues (hemolysis, fill volume, time, temperature, storage conditions) and the interference of many commonly prescribed drugs. The pathologist can serve an important role in the evaluation of a patient for a bleeding or thrombotic disorder. Using defined algorithms, hemostasis testing can proceed in a logical fashion and be reported using patient-specific comments that take into account clinical history and medication therapy. This approach can improve the diagnostic process, preventing misdiagnoses and leading to a decreased time to diagnosis and an improved utilization of laboratory resources.
- 7 February 2014
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 40 (02) , 195-204
Algorithmic Approaches to Hemostasis Testing
There are many unique issues that may make a pathologist's consultation helpful in hemostasis testing. Besides the rapidly expanding knowledge of both bleeding and thrombotic disorders and a wide test menu, hemostasis testing is very sensitive to preanalytical issues (hemolysis, fill volume, time, temperature, storage conditions) and the interference of many commonly prescribed drugs. The pathologist can serve an important role in the evaluation of a patient for a bleeding or thrombotic disorder. Using defined algorithms, hemostasis testing can proceed in a logical fashion and be reported using patient-specific comments that take into account clinical history and medication therapy. This approach can improve the diagnostic process, preventing misdiagnoses and leading to a decreased time to diagnosis and an improved utilization of laboratory resources.
- 10 December 2013
- Published by Springer Nature
- p. 1-37
Laboratory Analysis of Coagulation